Cost of low-value prescribing increasing despite fall in items

Despite a fall in prescription numbers for low-value treatments, the overall cost of prescribing these items in English primary care has risen, according to new research published by the Journal of the Royal Society of Medicine.

Costs of some low-value treatments have risen dramatically. | iStock
Costs of some low-value treatments have risen dramatically. | iStock

Researchers from the Nuffield Department of Primary Care Health Sciences at the University of Oxford found there were almost one million fewer prescriptions for low-value items between July 2016 and June 2017, compared with the previous year. However, costs increased by £4.5 million from 2016/17 to 2015/16.

Further information

JSM study

Low-value treatments are those deemed by NHS England to be ineffective, over-priced and of low clinical value.

The researchers found that while the cost per item has remained stable for most low-value treatments, for three items identified by NHS England, liothyronine, trimipramine and the unlicensed drug co-proxamol, the cost has risen dramatically, by £73, £168 and £71 per prescription, respectively.

Lead researcher Dr Ben Goldacre said: 'Co-proxamol, liothyronine and trimipramine illustrate a concerning phenomenon, where despite successful efforts to limit prescribing numbers, costs have risen sharply.'

Giving co-proxamol as an example, Dr Goldacre explained: 'It’s expensive because it was removed from the drug tariff, meaning that any prescriptions for it have to be sourced as a ‘special’ order. There is limited regulation of the cost of such special orders, making real world cost savings on such drugs difficult until there are a very small number of total prescriptions.'

The researchers found a strong association between practices with a higher proportion of patients over 65 and low-value prescribing. They also found prescribing behaviour clustered by CCG.

In addition to the national results presented in the paper, the researchers also shared all data on prescribing at all individual NHS practices. This is published through an interactive website, OpenPrescribing.net, which can be used by GPs, local commissioners, and even patients, to see where there are possible savings opportunities for individual prescribers.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more